PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  05/27 04:03:15 pm EDT
53.91 USD   -0.15%
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Booster shots needed against omicron, CDC studies show

01/21/2022 | 02:56pm EDT

NEW YORK (AP) — Three studies released Friday offered more evidence that COVID-19 vaccines are standing up to the omicron variant, at least among people who received booster shots.

They are the first large U.S. studies to look at vaccine protection against omicron, health officials said.

The papers echo previous research — including studies in Germany, South Africa and the U.K. — indicating available vaccines are less effective against omicron than earlier versions of the coronavirus, but also that boosters doses rev up virus-fighting antibodies to increase the chance of avoiding symptomatic infection.

The first study looked at hospitalizations and emergency room and urgent care center visits in 10 states, from August to this month.

It found vaccine effectiveness was best after three doses of the Pfizer or Moderna vaccines in preventing COVID-19-associated emergency department and urgent care visits. Protection dropped from 94% during the delta wave to 82% during the omicron wave. Protection from just two doses was lower, especially if six months had passed since the second dose.

Officials have stressed the goal of preventing not just infection but severe disease. On that count, some good news: A third dose was at least 90% effective at preventing hospitalizations for COVID-19, both during the delta and omicron periods, the study also found.

The second study focused on COVID-19 case and death rates in 25 states from the beginning of April through Christmas. People who were boosted had the highest protection against coronavirus infection, both during the time delta was dominant and also when omicron was taking over.

Those two articles were published online by the Centers for Disease Control and Prevention.

The Journal of the American Medical Association published the third study, also led by CDC researchers. It looked at people who tested positive for COVID-19 from Dec. 10 to Jan. 1 at more than 4,600 testing sites across the U.S.

Three shots of the Pfizer and Moderna vaccines were about 67% effective against omicron-related symptomatic disease compared with unvaccinated people. Two doses, however, offered no significant protection against omicron when measured several months after completion of the original series, the researchers found.

“It really shows the importance of getting a booster dose,” said the CDC’s Emma Accorsi, one of the study’s authors.

Americans should get boosters if at least five months have passed since they completed their Pfizer or Moderna series, but millions who are eligible have not gotten them.

“If you are eligible for a booster and you haven't gotten it, you are not up to date and you need to get your booster,” CDC Director Dr. Rochelle Walensky said during a White House briefing Friday.

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 8.73% 147.66 Delayed Quote.-41.86%
PFIZER, INC. -0.15% 53.91 Delayed Quote.-8.70%
All news about PFIZER, INC.
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabote..
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
05/26ZOOM VIDEO COMMUNICATIONS, INC. : An attempt to reconnect
05/26Pfizer Receives US FDA Fast Track Designation for Ervogastat/Clesacostat Combination to..
MT
05/26Malawi Among 5 First Five African Countries to Benefit From Pfizer Health Accord
AQ
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
BU
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
CI
05/26Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Bill..
AQ
05/26Supreme Court says watchdogs should pay fees
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,99x
Yield 2022 3,01%
Capitalization 302 B 302 B -
EV / Sales 2022 2,76x
EV / Sales 2023 3,56x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,91 $
Average target price 57,50 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-8.70%302 483
JOHNSON & JOHNSON5.86%472 231
ROCHE HOLDING AG-12.16%282 336
ELI LILLY AND COMPANY17.11%282 164
ABBVIE INC.10.78%266 074
NOVO NORDISK A/S-3.80%242 093